The facts are going against the narrative. The state run Newspeak Ministry of Truth (MSM, Social Media/government/woke/Hollywood) are having a hard time keeping the lid on the fact that the vax is failing and Ivermectin is working.

This is a relatively long post, but I have broken it up into sections for easy digestion. The net of it is how we are being lied to by Government/Pharma and that lie is being covered up by Big Tech/MSM/Social Media. The WEF is trying to use it for the Great Reset, but the facts are there to show the big lie.

I am giving you scientific information to make your own decisions.

Here are the facts:

ISRAEL – THE MOST VACCINATED COUNTRY

From the Times of Israel. More COVID cases confirmed in Israel in January than all of 2021, data shows:

The most vaccinated country in the world has the highest percentage of Covid.

There were more COVID-19 cases identified in Israel during January this year than the entirety of 2021, according to a report released Thursday.

The Coronavirus National Information and Knowledge Center said some 960,500 coronavirus cases were identified during 2021, while in January alone, as of Wednesday, more than 1,160,000 have tested positive.

The massive rise in cases has been blamed on the fast-spreading Omicron variant. On Wednesday, 67,723 new cases were recorded, according to Health Ministry data published Thursday. With more than 307,000 PCR and antigen tests carried out on Wednesday, the positivity rate stood at 24.58 percent.

As of Thursday afternoon, 480,501 Israelis were actively infected, with 2,483 hospitalized, 931 of those in serious condition, and 212 of them on ventilators. A week ago, serious cases stood at 587, and two weeks ago the figure was just 283.

Over the past week, more than 520,000 Israelis have tested positive for COVID, with experts believing that the actual figure could be several times higher. Also in the past week, 146 Israelis with COVID died — a 73.8% increase over the previous week — bringing the total death toll since the start of the pandemic to 8,541. A month ago, the average weekly death toll was less than 10.

Click on the above link for more.

JAPAN SWITCHES FROM THE JAB TO IVERMECTIN AND VOILA, IT’S WORKING AGAINST OMICRON AND ALL STRAINS (note at the bottom where the USA still “has problems with it”)

Ivermectin Shows Antiviral Effect Against Omicron: Japanese Pharma Firm

A Japanese conglomerate that is studying the anti-parasitic drug ivermectin has found that the medication had an antiviral effect on Omicron, according to joint non-clinical research.

Kowa Co. Ltd., a conglomerate with interests in trading, hospitality, and electronics, along with health and medical applications, issued a press release (pdf) on Jan. 31 stating that ivermectin has been found to be effective against Omicron in in vitro studies. The firm is also in the process of carrying out a Phase 3 clinical trial on the use of ivermectin to treat COVID-19 patients, though the company’s remarks on effectiveness pertain to the findings of lab-based research.

Kowa representatives didn’t respond to a request for comment by press time.

The company, working with Kitasato University based in Tokyo, said that ivermectin has the “same antiviral effect” on all “mutant strains,” including Alpha, Delta, and Omicron. Kowa added that ivermectin suppresses invasion of the virus and inhibits its replication.

“[Ivermectin] is expected to be applied as a therapeutic drug (tablet) for all new coronavirus infectious diseases,” the report said.

Ivermectin has been used by the World Health Organization for over 30 years to treat parasitic infections. Volunteers have distributed the drug in African countries where it has been found to be extremely effective, said the Kowa report.

However, the treatment has been mired in controversy during recent times as the U.S. Food and Drug Administration (FDA) has not approved the use of ivermectin as a treatment for COVID-19, even though the drug is used in humans to treat a variety of conditions.

Dr. Paul Marik, a supporter of using ivermectin, testified that ivermectin “is one of the safest drugs on the face of this planet.”

Marik, who is a co-founder of the physician-comprised advocacy group Front Line COVID-19 Critical Care Alliance, said ivermectin is approved for the treatment of viruses in 79 countries.

“So somehow Japanese people, Indian people, Brazilian people can tolerate it safely, but it’s toxic in Americans. You have to be kidding,” Marik said.

JOHN’S HOPKINS SHOWS GOVERNMENT CURE WORSE THAN THE DISEASE

Johns Hopkins Study Shows Government Cure for COVID Was Worse Than Disease, Lockdown Benefit Provided No Mitigation of Death from Virus

WASHINGTON – […] The lockdowns during the early phase of the pandemic in 2020 reduced COVID-19 mortality by about 0.2%, said the broad review of multiple scientific studies.

“We find no evidence that lockdowns, school closures, border closures, and limiting gatherings have had a noticeable effect on COVID-19 mortality,” the researchers wrote. But the research paper said lockdowns did have “devastating effects” on the economy and contributed to numerous social ills.

“They have contributed to reducing economic activity, raising unemployment, reducing schooling, causing political unrest, contributing to domestic violence, and undermining liberal democracy,” the report said.

“Such a standard benefit-cost calculation leads to a strong conclusion: lockdowns should be rejected out of hand as a pandemic policy instrument,” the paper concluded. (read more)

MALONE IVERMECTIN STUDY SHOWS COVID BEING CURED

Strictly regular use of ivermectin as prophylaxis for COVID-19 leads to a 90% reduction in COVID-19 mortality rate, in a dose-response manner: definitive results of a prospective observational study of a strictly controlled 223,128 population from a city-wide program in Southern Brazil

The Study:

Background: Previously, we demonstrated that ivermectin use as prophylaxis for COVID-19 was associated with reductions in COVID-19 infection, hospitalization, and mortality rates, and in the risk of dying from COVID-19, irrespective of regularity and accumulated use of ivermectin, in an observational, prospectively obtained data from a strictly controlled city-wide program in a city in Southern Brazil (Itajaí, SC, Brazil) of of medically-based, optional use of ivermectin as prophylaxis for COVID-19.

In this study, our objective was to explore the data obtained from the program to evaluate whether the level of regularity of ivermectin use impacted in the reductions in these outcomes, aiming to determine if ivermectin showed a progressive dose-, regularity-response in terms of protection from COVID-19 and COVID-19 related outcomes.

Materials and methods: This is a prospective observational study of the program mention above, that used ivermectin at a dose of 0.2mg/kg/day for two consecutive days, every 15 days. We obtained and analyzed the data regarding the accumulated dose of ivermectin use, in addition to age and comorbidities, to analyze the patterns of reduction of COVID-19 infection, hospitalization, and mortality rates, and risk of dying from COVID-19, according to the regularity and amount of ivermectin used in a 5-month period.

Following definitions of regularity, we considered as strictly regular subjects that used at least 180mg of ivermectin (180mg = 30 tablets), and as sporadic users subjects that used 60mg (= 10 tablets) or less during the 5-month period.

Comparisons between subjects that did not use ivermectin and these two levels of regularity of ivermectin use were performed. Analysis of the intermediate levels of ivermectin use are present in the supplement appendix of this study. To analyze hospitalization and mortality rates, we utilized the database of COVID-19 infections of all participants, from Itajaí and outside. To analyze COVID-19 infection rate and risk of dying from COVID-19 we utilized the Itajaí city database.

Propensity score matching (PSM) was employed, followed by multivariate adjusted analysis for residual differences (doubly adjusted analysis).

Results:

• Of the 7,345 cases of COVID-19, 3,034 occurred in non-users, 1,627 in sporadic users, and 289 in strict users, while the remaining cases occurred in the intermediate levels of ivermectin use. Strict users were older (p < 0.0001) and non-significant higher prevalence of type 2 diabetes and hypertension.
• COVID-19 infection rate was 39% lower among strict users [4.03% infection rate; ( p < 0.0001] than in non-users (6.64% infection rate), and non-significant 11% reduction compared to sporadic users (4.54% infection rate) (n = 1,627 in each group; RR, 0.89; 95%CI 0.76 – 1.03; p = 0.11).
• Hospitalization rate was reduced by 100% in strict users, compared to non-users and to sporadic users, both before and after Propensity score matching ( p < 0.0001).
• After Propensity score matching, hospitalization rate was 35% lower among sporadic users than non-users (RR, 0.65; 95%CI, 0.44 – 0.70; p = 0.03).
• In propensity score matched groups, multivariate-adjusted mortality rate was 90% lower in strict users compared to non-users (p = 0.003) and 79% lower than in sporadic users (p = 0.05), while sporadic users had a 37% reduction in mortality rate compared to non-users (p = 0.043).
• Risk of dying from COVID-19 was 86% lower among strict users than non-users (p = 0.006) and marginally significant, 72% lower than sporadic users (p = 0.083), while sporadic users had a 51% reduction compared to non-users (p = 0.001).

Conclusion: Non-use of ivermectin was associated with a 10-times increase in mortality risk and 7-times increased risk of dying from COVID-19, compared to strictly regular use of ivermectin in a prospectively collected, strictly controlled population.

A progressive dose-response pattern was observed between level of ivermectin use and level of protection from COVID-19 related outcomes and consistent across different levels of ivermectin use.

---

The results of this study clearly demonstrate that prophylactic use of ivermectin must be initiated immediately for people in high risk categories in the United States and worldwide. This includes individuals with one or more co-morbidities and the middle aged/elderly. Our “design-to-fail” government funded clinical trials for early treatment and governmental obstructionism regarding life saving treatments to patients must end now.